Inpatient Opioid Administration Patterns Linked to Post-Discharge Use in Opioid-Naive Patients
Rates of opioid administration were found to be high in opioid-naive inpatients.
General Pain
Public Disclosure of New Drug and Biologics Application Filing With the FDA
Investigators sought to determine how frequently information treated as confidential with regard to New Drug Applications or Biologics License Applications is available to the public.
Reviewing Off-Label Uses of Gabapentinoids
As part of current efforts to reduce unnecessary opioid consumption, clinicians have increasingly prescribed gabapentinoids for a range of pain disorders.
FDA Draft Guidance Seeks to Improve Drug Abuse, Dependence Information in Labeling
The FDA is looking to make the information in the Drug Abuse and Dependence section of product labeling more consistent and clear through a new draft guidance.
Case Study: Progressive Abdominal Pain
A man presents to the emergency department with progressive, right-sided abdominal and flank pain for 3 days.
Review Investigates Adverse Effects of Cannabidiol
The use of cannabidiol (CBD), the non-intoxicating component of cannabis, has been associated with numerous adverse effects based on available evidence from animal and human studies.
The Need to Develop Evidence-Based Recommendations on Dietary Ingredients for Pain Management
The Holistic Evidence Review Board examined the merits of developing evidence-based dietary recommendations to help operators better manage pain caused by musculoskeletal injuries.
Benefits of a Standardized Pain Management Regimen in Inpatient Psychiatric Units
The implementation of a standardized medication regimen for pain management in incoming psychiatric inpatients may be associated with a reduction in the number of pages related to pain complaints received by on-call residents.
Novel Gene Mutation Provides Hope for Future Pain Treatment
Due to a genetic mutation, a woman was able to endure burns, bone fractures, and surgeries without pain.
Injectable Pain Med Recalled Due to Possible Microbial Contamination
A recall of 1 lot of Ketorolac Tromethamine Injection 60mg/2mL (30mg/mL) has been initiated by Sagent Pharmaceuticals following the discovery of microbial growth during a routine simulation of the manufacturing process. Concerns over the possible introduction of microorganisms into the product led the Company to issue the recall to the user level. The product is…
Next post in General Pain
